Company intelligence / Profile preview
ALPS Biotech Co., Ltd.
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
ALPS Biotech focuses on the discovery and development of new drugs from natural products using proprietary analytical platforms. Their pipeline includes preclinical candidates targeting cancer, infectious diseases, nervous system diseases, and radiation injuries. The company leverages proteomics and early cancer screening technologies to enhance treatment effectiveness and quality of life for end-stage cancer patients. No clinical trial results have been published as of January 2025.
- Therapeutic areas
- OtherOncologyNeurologyInfectious Diseases
- Modalities
- Herbal medicineSmall molecule drugMonoclonal antibody
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on ALPS Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALPS Biotech Co., Ltd..